Patients with psoriatic arthritis and axial spondyloarthritis may be able to safely taper tumor necrosis factor inhibitors using a treat-to-target approach, new research indicates.
Patients with psoriatic arthritis and axial spondyloarthritis may be able to safely taper tumor necrosis factor inhibitors using a treat-to-target approach, new research indicates.
Patients with psoriatic...